2.3. Patient inclusion criteria

Adults (age ≥ 18 years) with T2D who had received BI‐based therapy as outpatients for ≥3 months were eligible for inclusion in the study. Study subjects were followed‐up for ≥3 months prior to enrolment at the respective study center, with HbA1c and fasting plasma glucose (FPG) measurements available 1 month before entering the study. Because the present study was an observational study, no medication was provided by the sponsor. The use of OADs and prandial insulin, as well as the BI dose, were chosen at the participating physicians' discretion in line with treatment guidelines and local label indications.